

UC Davis

UC Davis Previously Published Works

Title

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment.

Permalink

<https://escholarship.org/uc/item/0417c73v>

Journal

Journal of neurodevelopmental disorders, 15(1)

ISSN

1866-1947

Authors

Palumbo, Joseph M
Thomas, Brian F
Budimirovic, Dejan
[et al.](#)

Publication Date

2023

DOI

10.1186/s11689-023-09475-z

Peer reviewed

REVIEW

Open Access



Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment

Joseph M. Palumbo¹, Brian F. Thomas², Dejan Budimirovic^{3,4}, Steven Siegel⁵, Flora Tassone^{6,7}, Randi Hagerman^{6,8}, Christopher Faulk⁹, Stephen O'Quinn^{1*} and Terri Sebree¹

Abstract

Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive function and in the pathogenesis of fragile X syndrome (FXS). This review describes the ECS, its role in the central nervous system, how it is dysregulated in FXS, and the potential role of cannabidiol as a treatment for FXS. FXS is caused by deficiency or absence of the fragile X messenger ribonucleoprotein 1 (*FMR1*) protein, FMRP, typically due to the presence of >200 cytosine, guanine, guanine sequence repeats leading to methylation of the *FMR1* gene promoter. The absence of FMRP, following *FMR1* gene-silencing, disrupts ECS signaling, which has been implicated in FXS pathogenesis. The ECS facilitates synaptic homeostasis and plasticity through the cannabinoid receptor 1, CB₁, on presynaptic terminals, resulting in feedback inhibition of neuronal signaling. ECS-mediated feedback inhibition and synaptic plasticity are thought to be disrupted in FXS, leading to overstimulation, desensitization, and internalization of presynaptic CB₁ receptors. Cannabidiol may help restore synaptic homeostasis by acting as a negative allosteric modulator of CB₁, thereby attenuating the receptor overstimulation, desensitization, and internalization. Moreover, cannabidiol affects DNA methylation, serotonin 5HT_{1A} signal transduction, gamma-aminobutyric acid receptor signaling, and dopamine D₂ and D₃ receptor signaling, which may contribute to beneficial effects in patients with FXS. Consistent with these proposed mechanisms of action of cannabidiol in FXS, in the CONNECT-FX trial the transdermal cannabidiol gel, ZYN002, was associated with improvements in measures of social avoidance, irritability, and social interaction, particularly in patients who are most affected, showing $\geq 90\%$ methylation of the *FMR1* gene.

Keywords Fragile X syndrome, Endocannabinoid system, Cannabinoid receptors, Cannabidiol

*Correspondence:

Stephen O'Quinn
Oquinn@Zynerba.com

¹ Zynerba Pharmaceuticals Inc., Devon, PA, USA

² Empirical Pharmaceutical Services, LLC, Manteo, NC, USA

³ Departments of Psychiatry and Neurogenetics, Fragile X Clinic, Kennedy Krieger Institute, Baltimore, MD, USA

⁴ Department of Psychiatry & Behavioral Sciences-Child Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA

⁵ Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

⁶ Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, CA, USA

⁷ Department of Biochemistry and Molecular Medicine, School of Medicine, University of California-Davis, Sacramento, CA, USA

⁸ Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA

⁹ Department of Animal Science, University of Minnesota, St. Paul, MN, USA



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Fragile X syndrome

Fragile X syndrome (FXS) is a neurodevelopmental genetic disorder that has a prevalence of approximately 1 in 4000 males and 1 in 6000 females [1]. The main genetic mutation that causes FXS is a trinucleotide repeat expansion of the sequence cytosine, guanine, guanine (CGG), with 200 or more repeats in the 5' untranslated promoter region of the fragile X messenger ribonucleoprotein 1 (*FMRI*) gene (>200 repeats represents full mutation [FM]), which encodes the FMRP protein and is located on the X chromosome [2, 3]. FM leads to epigenetic methylation of the gene and consequent absence of *FMRI* mRNA transcription and translation of FMRP [2, 4–6]. Thus, FXS is caused by the deficit or absence of FMRP [7], an RNA-binding protein important for normal synaptic function, synaptic plasticity, and for the development of neuronal connections over time during brain maturation [8].

FXS is associated with a wide range of neurobehavioral impairments in skills (i.e., cognitive, language) and behaviors, including autism spectrum disorder (ASD), anxiety, aggression toward others, irritability, temper tantrums, shyness, and preference for solitary activities [9–11]. In general, the FXS neurocognitive and behavioral phenotype depends on the amount of FMRP that is produced, which is determined in part by the degree of the methylation of *FMRI* [12, 13]. Males with the FM and full methylation generally do not produce FMRP, whereas in females with the FM and full methylation the protein can range from near normal to significantly reduced expression of FMRP, depending on the pattern of X-inactivation in the affected female [14, 15]. In general, patients with FXS with a higher degree of methylation have a more severe phenotype such as lower IQ, and may have more severe symptoms of ASD, although there is wide variability for any given level of methylation [12, 15–17]. Individuals with a high degree of mosaicism due to the presence of cells carrying FM alleles and cells carrying alleles in the premutation range (i.e., 55 to 200 CGG repeats) or unmethylated FM alleles may produce elevated *FMRI* mRNA, which in itself can cause RNA toxicity to the cells of the central nervous system (CNS) [18, 19]. Those with FM and full methylation of *FMRI* produce reduced amounts of *FMRI* mRNA and little to no FMRP [12]. Therefore, they resemble the classical and most severe phenotype of FXS, characterized by lack of FMRP, which is recapitulated by the knockout mouse model of FXS [20]. Despite decades of preclinical research and interventional clinical trials, no approved treatments exist for FXS [21].

Purpose of this review

Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive function and the pathogenesis of FXS. This review describes the ECS, its role in the CNS, how it is dysregulated in FXS, and the potential role of cannabidiol as a treatment for FXS.

Role of the ECS in the CNS

The ECS is postulated to play a role in neuronal development and function, including facilitating synaptic homeostasis and plasticity [22]. The ECS primarily includes the endocannabinoids, 2-arachidonoylglycerol (2-AG) and anandamide (AEA), and the cannabinoid G-protein-coupled receptors, cannabinoid receptor 1 (CB₁) and cannabinoid receptor 2 (CB₂) [23, 24]. CB₁ and CB₂ are selectively expressed in various tissues [23, 24]. CB₁ receptors are expressed in the brain and are present at lower concentrations in a variety of peripheral tissues and cells. Brain regions that possess high levels of CB₁ receptors include the neocortex, cerebellum, and fore-brain structures, as well as the basal ganglia and limbic system areas that contribute to learning and memory, executive functioning, social interaction, and behavior and emotion. CB₂ receptors are expressed primarily in the immune and hematopoietic systems, as well as in the brain, pancreas, and bone.

In the brain, endocannabinoids are synthesized and released “on demand” from postsynaptic membrane-bound phospholipids in response to neuronal signaling and act as retrograde signaling molecules across the synaptic cleft to stimulate CB₁ receptors on the presynaptic terminal (Fig. 1) [23, 25] and attenuate further activity through an inhibitory feedback loop. Enzymes that function in synthesizing 2-AG include phospholipase C, diacylglycerol kinase- κ (DGK κ), and diacylglycerol lipase (DAGL) [23, 26]. At developed synapses, 2-AG released from postsynaptic terminals binds to presynaptic CB₁ receptors to inhibit the secretion of both excitatory and inhibitory neurotransmitters [27]. As mentioned above, the elements that comprise the ECS (i.e., the endocannabinoids and their receptors, CB₁ and CB₂) are located in the CNS [28–30]. Evidence indicates that the ECS has an important role in the CNS and alterations in the ECS in experimental animal models results in profound changes in cognition and behavior [31, 32]. Thus, as the ECS appears to regulate neuronal development and function, particularly synaptic homeostasis and plasticity [22], pharmacological intervention of this pathway, when disrupted, could prove to be a beneficial approach for the treatment of cognitive and behavioral problems. Consistent with this hypothesis, several drugs that target the




Fig. 1 Endocannabinoid-mediated signaling in the CNS in the normal state. In a normal state with *FMR1* protein present, (1) FMRP supports expression of DGKk and traffics DAGL mRNA, which results in (2) normal production of 2-AG and release into the synaptic cleft, which (3) stimulates presynaptic CB₁ receptors resulting in (4) retrograde inhibitory signaling and (5) optimal release of glutamate and activation of mGluR5 receptors and (6) modulation of GABAergic function. 2-AG, 2-arachidonoylglycerol; β-arr, β-arrestin; CB₁, cannabinoid type 1 receptor; CNS, central nervous system; DAG, diacylglycerol; DAGL, diacylglycerol lipase; DGKk, diacylglycerol kinase- κ ; FMRP, *FMR1* protein; G, G proteins; GABA, γ -aminobutyric acid; mGluR5, group I metabotropic glutamate receptor 5; mRNA, messenger RNA; PA, phosphatidic acid; PIP2, phosphatidylinositol-4,5-bisphosphate; PLC, phospholipase C

ECS are undergoing clinical development for neurodevelopmental and neuropsychiatric disorders [33–35].

Dysregulation of the ECS in FXS

The functional consequences of significantly reduced or absent FMRP in people with FXS likely reflect changes in both developmental and dynamic regulation of multiple intracellular processes involved in controlling the structure and function of the synapses within the CNS. FMRP is a critical element of translational control in dendritic polyribosomes that has been implicated in the repression of mRNA translation during trafficking to dendrites and synapses [36]. Aberrant synaptic protein synthesis due to alterations in FMRP levels has been proposed as a possible pathway leading to autistic phenotypes [37]. With respect to the ECS, FMRP has a recognition motif for DAGL mRNA [27]. When FMRP is translated and binds to DAGL mRNA in the polyribosome, it acts as a translational repressor while it traffics the mRNA to the post-synaptic dendritic terminal. It has been suggested

that decreased or absent FMRP disrupts normal DAGL trafficking and the formation of functional postsynaptic group I metabotropic glutamate receptor 5 (mGluR5)-DAGL complexes and disables on-demand endocannabinoid release and retrograde signaling in FXS, leading to ectopic production of 2-AG [27]. The resulting overstimulation of presynaptic CB₁ receptors then causes β-arrestin recruitment and phosphorylation, internalization, and desensitization of CB₁ receptors, and the dysregulation of retrograde endocannabinoid signaling in response to neuronal activity [38]. Therefore, absence of FMRP dysregulates the “on-demand” release of 2-AG via DAGL, thereby disrupting normal ECS function in feedback inhibition and synaptic plasticity (Fig. 2) [27, 39]. The loss of synaptic plasticity may result in deficits in learning, memory, and behavioral and emotional responsiveness observed in FXS and other behavioral disorders [27, 40]. Specifically, reductions of FMRP are thought to impair ECS-mediated regulation of glutamate signaling and gamma-aminobutyric acid (GABA)ergic signaling




Fig. 2 ECS dysfunction in FXS due to lack of FMRP. Lack of FMRP in FXS leads to (1) reduced expression of DGKk and abnormal trafficking of DAGL mRNA, which results in (2) ectopic/abnormal production of 2-AG and release into the synaptic cleft, which causes (3) β -arrestin recruitment, internalization, and desensitization of CB₁ receptors, resulting in (4) loss of the normal retrograde inhibitory signaling and (5) increased glutamate release and activation of mGluR5 receptors and (6) altered GABA release. 2-AG, 2-arachidonoylglycerol; β -arr, β -arrestin; CB₁, cannabinoid type 1 receptor; CNS, central nervous system; DAG, diacylglycerol; DAGL, diacylglycerol lipase; DGKk, diacylglycerol kinase- κ ; ECS, endocannabinoid system; FMRP, *FMR1* protein; FXS, fragile X syndrome; G, G proteins; GABA, γ -aminobutyric acid; mGluR5, group I metabotropic glutamate receptor 5; mRNA, messenger RNA; PA, phosphatidic acid; PIP2, phosphatidylinositol-4,5-bisphosphate; PLC, phospholipase C

in FXS [27, 39, 41]. Likewise, reductions in FMRP have been associated with altered ECS-mediated responses at GABAergic synapses [39, 41], suggesting disruption of retrograde signaling by the ECS at inhibitory synapses involved in GABAergic function in FXS. This disruption in ECS-mediated negative feedback of neuronal signaling may represent one of the key physiologic mechanisms underlying both the development of FXS neuronal dysfunctions and the expression of more debilitating behavioral symptoms, including severe social anxiety and irritability.

There is considerable preclinical and clinical evidence to support a link between the ECS and FXS and ASD phenotypes. For example, treatment of *FMR1* knockout mice with monoacylglycerol lipase (MAGL) inhibitors to increase endocannabinoid signaling tone has been shown to normalize cortical responses to sound and diminish anxiety-like behaviors [42] and restore mGluR5-mediated long-term depression in brain slices taken from the ventral striatum of *FMR1* knockout mice [27]. Moreover,

mice lacking the CB₁ receptor display several changes in social behavior and communication both during early development and in adulthood, further supporting the role of the ECS in FXS- and ASD-like phenotypes [43]. Indeed, inhibition of the endocannabinoid producing enzyme, DAGL- α , induces ASD-like behavior and other co-morbid phenotypes in adult C57BL/J mice [44]. In humans, rare heterozygous genetic (missense) variants in *CNR1* and *DAGLA*, the genes encoding the CB₁ receptor and the DAGL- α enzyme, have been shown to be associated with sleep and memory disorders—alone or in combination with anxiety, and with seizures and neurodevelopmental disorders, including abnormalities of behavior and brain morphology similar to those observed in FXS patients [45]. In contrast, rare missense variants in *MGLL*, *FAAH*, and *CNR2*, the genes encoding monoacylglycerol lipase, fatty acid amide hydrolase, and the CB₂ receptor, respectively, were not associated with any abnormal neurological phenotypes in the patients examined in this study. Similarly, in clinical studies

investigating gaze duration to facial stimuli, a behavior frequently altered in ASD and FXS patients, polymorphisms in the *CNR1* gene were shown to modulate striatal responses and gaze duration to happy faces [46, 47]. Together, these findings implicate the endocannabinoid-CB₁ receptor signaling system in psychological and behavioral conditions involving altered responsiveness to emotional and social stimuli such as those observed in FXS (for reviews, see references [48–50]).

Cannabidiol effects on the CNS

Cannabidiol, the main non-euphoric component of the cannabis plant, has a variety of effects on the ECS and has been studied in a variety of neurodevelopmental and neuropsychiatric disorders (for reviews, see references [51, 52]). Cannabidiol acts as a negative allosteric modulator of 2-AG at CB₁, thereby attenuating 2-AG-mediated CB₁ receptor activation, internalization, and desensitization [53, 54]. Moreover, cannabidiol may reduce CB₁ receptor internalization even in the absence of 2-AG, thereby

increasing the relative membrane expression of functional CB₁ receptors [53–57]. In its activity as a negative allosteric modulator, cannabidiol does not compete with 2-AG binding to CB₁, but rather shifts the dose response to the right and reduces the apparent potency of 2-AG signaling through the CB₁ receptor [53]. Moreover, cannabidiol interacts with fatty acid-binding proteins (FABP) that transport AEA to fatty acid amide hydrolase (FAAH), and reduces transport and catabolic loss of AEA [54, 58–62]. Introduction of exogenous cannabidiol, therefore, is hypothesized to restore functional retrograde ECS signaling, thereby normalizing the ECS in the absence of FMRP (Fig. 3).

If the net effect of loss of FMRP is diminished cannabinoid signaling due to receptor desensitization as an adaptation to 2-AG overproduction [38], then treatment with MAGL inhibitors to increase endocannabinoid tone could overcome desensitization of the CB₁ receptor and show therapeutic potential [27, 42]. However, this approach would also lead to further desensitization and




Fig. 3 Proposed mechanism(s) of action of cannabidiol on the ECS in FXS. Treatment of FXS with cannabidiol is proposed to lead to (1) cannabidiol's acting as a negative allosteric modulator (NAM) at the CB₁ receptors, resulting in (2) reduction of β -arrestin recruitment, along with prevention of internalization and desensitization of CB₁ receptors in the presence of ectopic/abnormal 2-AG, which leads to (3) restoration of retrograde inhibitory signaling and (4) reduction in glutamate release and activation of mGluR5 receptors and (5) restoration of GABAergic function. 2-AG, 2-arachidonoylglycerol; β -arr, β -arrestin; CB₁, cannabinoid type 1 receptor; CBD, cannabidiol; DAG, diacylglycerol; DAGL, diacylglycerol lipase; DGKk, diacylglycerol kinase- κ ; ECS, endocannabinoid system; FMRP, *FMR1* protein; FXS, fragile X syndrome; G, G proteins; GABA, γ -aminobutyric acid; mGluR5, group 1 metabotropic glutamate receptor 5; PA, phosphatidic acid; PIP2, phosphatidylinositol-4,5-bisphosphate; PLC, phospholipase C

internalization of CB₁ and ultimately exacerbate the loss of retrograde signaling at the presynaptic terminal. In contrast, cannabidiol treatment may increase localization of functional CB₁ receptors in the presynaptic membrane and shift the 2-AG dose response curve at the CB₁ receptor to the right [53], diminishing CB₁ receptor desensitization due to ectopic 2-AG release and enabling CB₁ receptor function to contribute to synaptic plasticity. An interesting analogy is that desensitization and internalization of CB₁ receptors in FXS is similar to hearing loss. Hearing loss can be overcome by increasing the volume of the sound over “normal” levels (similar to elevating 2-AG levels with MAGL inhibitors) but can cause further damage to the hairs (stereocilia) in the ears leading to further hearing loss and exacerbating the problem (similar to producing further CB₁ receptor desensitization and internalization due to the increased endocannabinoid tone caused by treatment with MAGL-inhibitors). Cannabidiol by comparison, increases the levels of functional cannabinoid receptors at the plasma membrane, which could be viewed as restoring the responsivity of the hairs in the ear, and shifts the dose-response curve of 2-AG to the right (essentially lowering the background “noise”).

It is also important to note that there has been considerable preclinical and clinical interest in the role of group 1 metabotropic glutamate receptors in FXS (see [63] for review). In preclinical studies, *FMRI* knockout models in mice demonstrated that the absence of gene transcription and FMRP translation leads to increased protein synthesis at the postsynaptic membrane and (abnormal) enhancement of mGluR5 glutamatergic signaling and long-term depression, which are important components of synaptic plasticity, learning, and memory. Furthermore, administration of mGluR5 antagonists in *FMRI* knockout mice demonstrated a variety of benefits in this preclinical FXS model phenotype, including reduced seizures and anxiety-like behaviors [64]. However, clinical studies with mGluR5 antagonists have failed to show significant therapeutic utility [65]. While these clinical trials using mGluR5 antagonists have failed to show clinical utility in FXS patients, mGluR5 is also an integral component of the endocannabinoid signalosome. Specifically, the mGluR5 receptor is coupled to DAGL in the post-synaptic density, and upon stimulation by glutamate, it causes the liberation of 2-AG. This 2-AG then enables endocannabinoid-mediated retrograde signaling to the presynaptic CB₁ receptor to produce long-term depression of glutamatergic transmission and other cellular signaling adaptations involved in neuronal plasticity, learning, and memory. In this scenario, mGluR5 antagonists could diminish excessive glutamatergic tone, as well as reduce whatever coupling of the mGluR5 receptor to endocannabinoid release is present and functional, but

this would ultimately decrease endocannabinoid retrograde signaling and impede synaptic plasticity. It would have no effect on the background “noise” due to ectopic 2-AG release and would only diminish glutamate-induced 2-AG release.

Cannabidiol effects on DNA methylation

As described earlier, the FMRP production is influenced by CGG repeat size and methylation [66]; however, the primary determinant is the degree to which *FMRI* alleles are methylated [15, 16]. The effect of a high degree of methylation differs in males and females: males with a hypermethylated FM generally do not produce FMRP, whereas females produce FMRP, with expression levels that correlate with the X-inactivation ratio of the affected allele. In females, inactivation of 1 of the 2 X chromosomes is a random process, potentially leading to differential intra and inter tissue patterns of FMRP expression. Furthermore, the normal, nonmutated X chromosome may also be affected by methylation and may produce less FMRP. The overall production of FMRP in females is determined by the extent of activation of the normal alleles.

Emerging evidence suggests that cannabidiol may regulate DNA methylation. Methionine synthesis is decreased by cannabidiol treatment [67]. Methionine serves as the substrate for methionine adenosyl transferase, which yields S-adenosylmethionine, which in turn is the key biochemical moiety involved in methyl group transfers to DNA through the action of DNA methyltransferases. This may lead to reduced DNA methylation. Cannabidiol was found to modulate DNA methylation in the prefrontal cortex and hippocampus of mice [68, 69]. In these pre-clinical studies, using the forced swim test model in mice, cannabidiol had an antidepressant-like effect and modulated DNA methylation in the prefrontal cortex and hippocampus, brain regions relevant for depression neurobiology [68]. Cannabidiol-treated mice showed a small skew toward global hypomethylation in hippocampal tissue [69]. In addition, genes for cell adhesion and migration, dendritic spine development, and excitatory postsynaptic potential were found to be enriched among the genes affected by cannabidiol-altered DNA methylation [69]. The effects of cannabidiol on DNA methylation in the FXS animal models have not been reported. These emerging results suggest that the DNA methylation epigenome may also be a key substrate for the long-term neurochemical and behavioral effects of cannabidiol.

Other effects of cannabidiol potentially related to FXS

Several other effects of cannabidiol may provide therapeutic benefit in patients with FXS. Serotonin 5HT_{1A} receptors have been implicated in anxiety and depression,

with most 5HT_{1A} receptor agonists exerting anxiolytic activity [70]. Cannabidiol binds to the 5HT_{1A} receptor with moderate affinity and possesses agonist efficacy in 5HT_{1A} signal transduction studies [71]. Cannabidiol has also been shown to act as a positive allosteric modulator at GABA_A receptors [72]. Cannabidiol's ability to enhance endocannabinoid levels and facilitate GABAergic transmission may serve to improve the balance in inhibitory and excitatory transmission and help restore neuronal function and synaptic plasticity in patients with FXS. Cannabidiol is also a dopamine D₂ partial agonist [73]. Moreover, cannabidiol interacts with dopamine D₃ receptors [74] and reduces the expression of dopamine D₃ receptors in a rat model of schizophrenia [75]. This is an area of active investigation and may indicate that cannabidiol has a fairly broad neuropharmacological mechanism of action.

CONNECT-FX trial with transdermal cannabidiol gel

Because of the proposed role of dysregulation of the ECS in FXS, a signal-finding, open-label trial [33] and a randomized, double-blind, placebo-controlled trial have been conducted with ZYN002 in patients with FXS. ZYN002 is a pharmaceutically manufactured permeation-enhanced transdermal cannabidiol gel in development for the treatment of behavioral symptoms in FXS. The open-label trial found that ZYN002 was well tolerated and was associated with reduced anxiety and behavioral symptoms in children and adolescents with FXS [33]. The results from the open-label trial led to a phase 3 randomized controlled trial of ZYN002 in patients with FXS. CONNECT-FX is the largest controlled trial ever performed in FXS [76] and is described in more detail in the accompanying article in this journal [77]. In the intent-to-treat population, numerical improvements in Aberrant Behavior Checklist-Community FXS (ABC-C_{FXS}) Social Avoidance, Irritability, and Socially Unresponsive/Lethargic subscale scores were greater in the ZYN002 group than in the placebo group; however, the differences were not statistically significant. A pre-planned ad hoc analysis, defined prior to breaking the study blind, was conducted to evaluate the efficacy of ZYN002 vs placebo in patients with $\geq 90\%$ methylation of the promoter region of the *FMRI* gene. In patients with $\geq 90\%$ methylation, ZYN002 was superior to placebo in multiple analyses. ZYN002 was associated with a statistically significant mean improvement from baseline in Social Avoidance vs placebo. In addition, the proportions of patients attaining a threshold of clinically meaningful within-patient change in Social Avoidance and Irritability were significantly greater with ZYN002 vs placebo. Moreover, there was a statistically significantly higher percentage of caregiver-reported improvements for Social Avoidance, Social

Interaction, and Irritable Behaviors with ZYN002 vs placebo. ZYN002 was also found to be well tolerated in this study. A post hoc analysis indicated that the treatment effect of ZYN002 in improvement of Social Avoidance was most pronounced in patients who had 100% methylation of their *FMRI* gene promoter, thereby supporting the idea that ZYN002 is most effective in patients with complete silencing of the *FMRI* gene. Thus, the results of the CONNECT-FX trial are consistent with the proposed mechanisms of action of cannabidiol in FXS described in this article.

Future directions

Much of the research on the roles of the ECS in FXS has been conducted in the past decade and is rapidly developing. The mechanisms discussed in this review are based largely on data obtained from animal models, which are amenable to experimental research, but which may not always accurately reflect the human disease process (e.g., the negative results obtained with mGluR5 antagonists in clinical studies in FXS). One area of preclinical research that may provide important insights is assessing the relative contributions of the effects of cannabidiol on the various implicated signaling pathways, such as CB₁ receptor signaling, DNA methylation, serotonin 5HT_{1A} signal transduction, GABA receptor signaling, and dopamine D₂ and D₃ receptor signaling. In clinical research, it would be beneficial to have more detailed assessments of the effects of acute and chronic administration of cannabidiol on specific regions of the brain [78, 79]. There is also a need for additional controlled clinical trials of cannabidiol in patients with neurodevelopmental disorders such as FXS and ASD. In particular, it will be important to identify appropriate target populations in FXS and ASD that may benefit most from cannabidiol treatment.

Conclusions

FXS is caused by deficiency or absence of FMRP, typically due to the presence of >200 CGG repeats and methylation in the promoter region of the *FMRI* gene. The absence of FMRP downregulates the ECS signaling, which has been implicated in FXS pathogenesis. Synaptic homeostasis and plasticity may be regulated by the ECS through the postsynaptic "on demand" production of endocannabinoids, which then bind to CB₁ receptors on presynaptic terminals, resulting in regulation of glutamate signaling and GABAergic signaling. The ECS-mediated feedback inhibition and synaptic plasticity are thought to be disrupted in FXS due to dysregulation of enzymes that are integral to the ECS (e.g., DAGL), leading to overstimulation, desensitization, and internalization of presynaptic CB₁ receptors. Cannabidiol may help restore synaptic homeostasis by acting as a negative

allosteric modulator of CB₁, thereby attenuating CB₁ receptor overstimulation, internalization, and desensitization. Moreover, cannabidiol has effects on DNA methylation, 5HT_{1A} signal transduction, GABA_A receptor signaling, and dopamine D₂ and D₃ receptor signaling, which may contribute to beneficial effects in patients with FXS. Consistent with these proposed mechanisms of action of cannabidiol in FXS, the transdermal cannabidiol gel, ZYN002, was associated with improvements in measures of social avoidance, irritability, and social interaction in the CONNECT-FX trial, particularly among patients with $\geq 90\%$ methylation of the *FMR1* gene.

Abbreviations

| | |
|----------------------|--|
| 2-AG | 2-Arachidonoylglycerol |
| ABC-C _{FXS} | Aberrant Behavior Checklist-Community Fragile X Syndrome |
| AEA | Anandamide |
| ASD | Autism spectrum disorder |
| CB1 | Cannabinoid receptor 1 |
| CB2 | Cannabinoid receptor 2 |
| CGG | Cytosine, guanine, guanine |
| CNS | Central nervous system |
| DAGL | Diacylglycerol lipase |
| DGK κ | Diacylglycerol kinase- κ |
| ECS | Endocannabinoid system |
| FAAH | Fatty acid amide hydrolase |
| FABP | Fatty acid-binding protein |
| FM | Full mutation |
| FXS | Fragile X syndrome |
| GABA | Gamma-aminobutyric acid |
| MAGL | Monoacylglycerol lipase |
| mGluR5 | Metabotropic glutamate receptor 5 |
| mRNA | Messenger RNA |

Acknowledgements

Not applicable.

Authors' contributions

Conceptualization: JP, BT, DB, SS, FT, RH, CF, SO, and TS; Methodology: JP, BT, DB, SS, FT, RH, CF, and SO; Investigation: BT, DB, FT, RH, and SO; Resources: DB, FT, RH, SO, and TS; Data curation: FT; Writing—original draft: JP, BT, and SO; Writing—review & editing: DB, SS, FT, RH, CF, and TS; Visualization: JP, BT, and SO; Supervision: JP, BT, and SO; Project administration: SO; Funding Acquisition: TS. The authors declare that they have no competing interests. The authors read and approved the final manuscript.

Funding

Zynerba Pharmaceuticals Inc., Devon, PA, USA, provided funding to *p*-value communications for support with technical writing, editing, and publication assistance.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

JMP was an employee of Zynerba Pharmaceuticals at the time of the manuscript development. BFT was a consultant to Zynerba Pharmaceuticals

at the time of the manuscript development. DB was an investigator for the CONNECT-FX study for Zynerba Pharmaceuticals. SS is on the Scientific Advisory Board for fragile X syndrome for Zynerba Pharmaceuticals. FT and CF have no competing interests. RH has received funding from Zynerba Pharmaceuticals for the conduct of the study as an investigator and is on scientific advisory board for fragile X syndrome for Zynerba Pharmaceuticals. SO, Q and TS are employees of Zynerba Pharmaceuticals.

Received: 15 March 2022 Accepted: 28 December 2022

Published online: 09 January 2023

References

- Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, et al. Incidence of fragile X syndrome by newborn screening for methylated *FMR1* DNA. *Am J Hum Genet.* 2009;85(4):503–14.
- Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. *Cell.* 1991;66(4):817–22.
- Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell.* 1991;65(5):905–14.
- Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. *Hum Mol Genet.* 1992;1(6):397–400.
- Zafarullah M, Tassone F. Molecular biomarkers in fragile X syndrome. *Brain Sci.* 2019;9(5):96.
- Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. *Nat Neurosci.* 2013;16(11):1530–6.
- Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr, Moine H, Kooy RF, et al. Fragile X syndrome. *Nat Rev Dis Primers.* 2017;3:17065.
- Sidorov MS, Auerbach BD, Bear MF. Fragile X mental retardation protein and synaptic plasticity. *Mol Brain.* 2013;6:15.
- Hagerman RJ. Fragile X syndrome. Molecular and clinical insights and treatment issues. *West J Med.* 1997;166(2):129–37.
- Tranfaglia MR. The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. *Dev Neurosci.* 2011;33(5):337–48.
- Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. *Pediatrics.* 2009;123(1):378–90.
- Budimirovic DB, Schlageter A, Filipovic-Sadic S, Protic DD, Bram E, Mahone EM, et al. A genotype-phenotype study of high-resolution *FMR1* nucleic acid and protein analyses in fragile X patients with neurobehavioral assessments. *Brain Sci.* 2020;10(10):694.
- Usdin K, Hayward BE, Kumari D, Lokanga RA, Sciascia N, Zhao XN. Repeat-mediated genetic and epigenetic changes at the *FMR1* locus in the fragile X-related disorders. *Front Genet.* 2014;5:226.
- Jiraanont P, Kumar M, Tang HT, Espinal G, Hagerman PJ, Hagerman RJ, et al. Size and methylation mosaicism in males with fragile X syndrome. *Expert Rev Mol Diagn.* 2017;17(11):1023–32.
- Pretto D, Yrigollen CM, Tang HT, Williamson J, Espinal G, Iwahashi CK, et al. Clinical and molecular implications of mosaicism in *FMR1* full mutations. *Front Genet.* 2014;5:318.
- Kim K, Hessel D, Randol JL, Espinal GM, Schneider A, Protic D, et al. Association between IQ and *FMR1* protein (FMRP) across the spectrum of CGG repeat expansions. *PLoS One.* 2019;14(12):e0226811.
- Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. *Ment Retard Dev Disabil Res Rev.* 2004;10(1):31–41.
- Schneider A, Winarni TI, Cabal-Herrera AM, Bacalman S, Gane L, Hagerman P, et al. Elevated *FMR1*-mRNA and lowered FMRP - a double-hit mechanism for psychiatric features in men with *FMR1* premutations. *Transl Psychiatry.* 2020;10(1):205.
- Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of *FMR1* messenger RNA. *Am J Med Genet.* 2000;94(3):232–6.

20. Pilpel Y, Kollerker A, Berberich S, Ginger M, Frick A, Mientjes E, et al. Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of *FMRI* knockout mice. *J Physiol*. 2009;587(Pt 4):787–804.
21. Lee AW, Ventola P, Budimirovic D, Berry-Kravis E, Visootsak J. Clinical development of targeted fragile X syndrome treatments: an industry perspective. *Brain Sci*. 2018;8(12):214.
22. Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. *Annu Rev Neurosci*. 2012;35:529–58.
23. Mouslech Z, Valla V. Endocannabinoid system: an overview of its potential in current medical practice. *Neuro Endocrinol Lett*. 2009;30(2):153–79.
24. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev*. 2006;58(3):389–462.
25. Vaughan CW, Christie MJ. Retrograde signalling by endocannabinoids. *Handb Exp Pharmacol*. 2005;(168):367–83. https://doi.org/10.1007/3-540-26573-2_12.
26. Reisenberg M, Singh PK, Williams G, Doherty P. The diacylglycerol lipases: structure, regulation and roles in and beyond endocannabinoid signalling. *Philos Trans R Soc Lond B Biol Sci*. 2012;367(1607):3264–75.
27. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. *Nat Commun*. 2012;3:1080.
28. Fernandez-Ruiz J, Galve-Roperh I, Sagredo O, Guzman M. Possible therapeutic applications of cannabis in the neuropsychopharmacology field. *Eur Neuropsychopharmacol*. 2020;36:217–34.
29. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A*. 1990;87(5):1932–6.
30. Hoffman AF, Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. *J Neurosci*. 2000;20(7):2470–9.
31. Castillo PE, Younts TJ, Chavez AE, Hashimoto-dani Y. Endocannabinoid signaling and synaptic function. *Neuron*. 2012;76(1):70–81.
32. Ohno-Shosaku T, Kano M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. *Curr Opin Neurobiol*. 2014;29:1–8.
33. Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. *J Neurodev Disord*. 2019;11(1):16.
34. Schmidt ME, Liebowitz MR, Stein MB, Grunfeld J, Van Hove I, Simmons WK, et al. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. *Neuropsychopharmacology*. 2021;46(5):1004–10.
35. Mayo LM, Asratian A, Linde J, Morena M, Haataja R, Hammar V, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. *Biol Psychiatry*. 2020;87(6):538–47.
36. Kelleher RJ 3rd, Bear MF. The autistic neuron: troubled translation? *Cell*. 2008;135(3):401–6.
37. Joo Y, Benavides DR. Local protein translation and RNA processing of synaptic proteins in autism spectrum disorder. *Int J Mol Sci*. 2021;22(6):2811.
38. Straiker A, Min KT, Mackie K. *Fmr1* deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons. *Neurobiol Dis*. 2013;56:1–5.
39. Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking *FMRP* and *BC1* RNA. *Neuropsychopharmacology*. 2010;35(7):1500–9.
40. Busquets-García A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. *Nat Med*. 2013;19(5):603–7.
41. Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. *J Neurosci*. 2010;30(16):5724–9.
42. Pirbhoy PS, Jonak CR, Syed R, Arqueta DA, Perez PA, Wiley MB, et al. Increased 2-arachidonoyl-sn-glycerol levels normalize cortical responses to sound and improve behaviors in *Fmr1* KO mice. *J Neurodev Disord*. 2021;13(1):47.
43. Fyke W, Alarcon JM, Velinov M, Chadman KK. Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-alpha, induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice. *Autism Res*. 2021;14(7):1375–89.
44. Fyke W, Premoli M, Echeverry Alzate V, Lopez-Moreno JA, Lemaire-Mayo V, Crusio WE, et al. Communication and social interaction in the cannabinoid-type 1 receptor null mouse: Implications for autism spectrum disorder. *Autism Res*. 2021;14(9):1854–72.
45. Smith DR, Stanley CM, Foss T, Boles RG, McKernan K. Rare genetic variants in the endocannabinoid system genes *CNR1* and *DAGLA* are associated with neurological phenotypes in humans. *PLoS One*. 2017;12(11):e0187926.
46. Chakrabarti B, Baron-Cohen S. Variation in the human cannabinoid receptor *CNR1* gene modulates gaze duration for happy faces. *Mol Autism*. 2011;2(1):10.
47. Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S. Variations in the human cannabinoid receptor (*CNR1*) gene modulate striatal responses to happy faces. *Eur J Neurosci*. 2006;23(7):1944–8.
48. Fyke W, Velinov M. *FMR1* and autism, an intriguing connection revisited. *Genes (Basel)*. 2021;12(8):1218.
49. Salcedo-Arellano MJ, Cabal-Herrera AM, Punatar RH, Clark CJ, Romney CA, Hagerman RJ. Overlapping molecular pathways leading to autism spectrum disorders, fragile X syndrome, and targeted treatments. *Neurotherapeutics*. 2021;18(1):265–83.
50. Tassanakijpanich N, Cabal-Herrera AM, Salcedo-Arellano MJ, Hagerman RJ. Fragile X syndrome and targeted treatments. *J Biomed Transl Res*. 2020;6(1):23–33.
51. Kwan Cheung KA, Mitchell MD, Heussler HS. Cannabidiol and neurodevelopmental disorders in children. *Front Psychiatry*. 2021;12:643442.
52. Garcia-Gutierrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. *Biomolecules*. 2020;10(11):1575.
53. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br J Pharmacol*. 2015;172(20):4790–805.
54. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Delta(9)-tetrahydrocannabinol negative modulators of the endocannabinoid system? A systematic review. *Br J Pharmacol*. 2015;172(3):737–53.
55. Pertwee RG, Ross RA, Craib SJ, Thomas A. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. *Eur J Pharmacol*. 2002;456(1-3):99–106.
56. Ryan D, Drysdale AJ, Pertwee RG, Platt B. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. *Eur J Neurosci*. 2007;25(7):2093–102.
57. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *Br J Pharmacol*. 2007;150(5):613–23.
58. Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). *J Biol Chem*. 2015;290(14):8711–21.
59. Kreutz S, Koch M, Bottger C, Ghadban C, Korf HW, Dehghani F. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. *Glia*. 2009;57(3):286–94.
60. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol*. 2001;134(4):845–52.
61. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabinol. *Br J Pharmacol*. 2008;153(2):199–215.
62. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Transl Psychiatry*. 2012;2:e94.
63. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. *Trends Neurosci*. 2004;27(7):370–7.
64. Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. *Psychopharmacology (Berl)*. 2012;219(1):47–58.

65. Grabb MC, Potter WZ. Central nervous system trial failures: using the fragile X syndrome-mGluR5 drug target to highlight the complexities of translating preclinical discoveries into human trials. *J Clin Psychopharmacol.* 2022;42(3):234–7.
66. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the *FMR1* gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. *Sci Transl Med.* 2011;3(64):64ra1.
67. Perry CJ, Finch P, Muller-Taubenberger A, Leung KY, Warren EC, Damstra-Oddy J, et al. A new mechanism for cannabidiol in regulating the one-carbon cycle and methionine levels in Dictyostelium and in mammalian epilepsy models. *Br J Pharmacol.* 2020;177(4):912–28.
68. Sales AJ, Guimaraes FS, Joca SRL. CBD modulates DNA methylation in the prefrontal cortex and hippocampus of mice exposed to forced swim. *Behav Brain Res.* 2020;388:112627.
69. Wanner NM, Colwell M, Drown C, Faulk C. Subacute cannabidiol alters genome-wide DNA methylation in adult mouse hippocampus. *Environ Mol Mutagen.* 2020;61(9):890–900.
70. Olivier JDA, Olivier B. Translational studies in the complex role of neurotransmitter systems in anxiety and anxiety disorders. *Adv Exp Med Biol.* 2020;1191:121–40.
71. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. *Neurochem Res.* 2005;30(8):1037–43.
72. Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. *Pharmacol Res.* 2017;119:358–70.
73. McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. *Am J Psychiatry.* 2018;175(3):225–31.
74. Bian YM, He XB, Jing YK, Wang LR, Wang JM, Xie XQ. Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation. *Acta Pharmacol Sin.* 2019;40(3):374–86.
75. Stark T, Di Bartolomeo M, Di Marco R, Dražanova E, Platania CBM, Iannotti FA, et al. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. *Biochem Pharmacol.* 2020;177:114004.
76. Berry-Kravis EM, Lindemann L, Jonch AE, Apostol G, Bear MF, Carpenter RL, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. *Nat Rev Drug Discov.* 2018;17(4):280–99.
77. Berry-Kravis E, Hagerman R, Budimirovic D, Erickson C, Heussler H, Tartaglia N, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). *J Neurodev Disord.* 2022;14(1):56. <https://doi.org/10.1186/s11689-022-09466-6>.
78. Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. *Neuropsychopharmacology.* 2019;44(8):1398–405.
79. Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). *J Psychopharmacol.* 2019;33(9):1141–8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

